Capital Asset Advisory Services LLC Decreases Position in Amgen Inc. (AMGN)
Capital Asset Advisory Services LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 7.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,582 shares of the medical research company’s stock after selling 215 shares during the period. Capital Asset Advisory Services LLC’s holdings in Amgen were worth $446,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Jackson Grant Investment Advisers Inc. increased its holdings in Amgen by 0.6% during the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after purchasing an additional 4 shares during the period. Conservest Capital Advisors Inc. increased its holdings in Amgen by 0.4% during the 2nd quarter. Conservest Capital Advisors Inc. now owns 3,130 shares of the medical research company’s stock worth $539,000 after purchasing an additional 13 shares during the period. M Holdings Securities Inc. increased its holdings in Amgen by 0.6% during the 1st quarter. M Holdings Securities Inc. now owns 2,825 shares of the medical research company’s stock worth $463,000 after purchasing an additional 18 shares during the period. Kovitz Investment Group Partners LLC increased its holdings in Amgen by 1.2% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 3,223 shares of the medical research company’s stock worth $529,000 after purchasing an additional 38 shares during the period. Finally, Middleton & Co Inc MA increased its holdings in Amgen by 2.3% during the 1st quarter. Middleton & Co Inc MA now owns 1,780 shares of the medical research company’s stock worth $292,000 after purchasing an additional 40 shares during the period. 78.09% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Capital Asset Advisory Services LLC Decreases Position in Amgen Inc. (AMGN)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2017/09/19/capital-asset-advisory-services-llc-decreases-position-in-amgen-inc-amgn.html.
Amgen Inc. (NASDAQ:AMGN) traded down 0.13% during mid-day trading on Tuesday, reaching $186.23. The company’s stock had a trading volume of 800,467 shares. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $191.10. The stock has a market capitalization of $135.89 billion, a price-to-earnings ratio of 16.96 and a beta of 1.35. The firm has a 50-day moving average of $175.65 and a 200-day moving average of $169.26.
Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.84 earnings per share. On average, equities research analysts expect that Amgen Inc. will post $12.57 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were issued a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a dividend yield of 2.47%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is presently 41.93%.
Several brokerages have weighed in on AMGN. BMO Capital Markets downgraded Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 price target on the stock. in a report on Friday, July 21st. They noted that the move was a valuation call. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $203.00 price target on shares of Amgen in a report on Thursday, September 7th. Jefferies Group LLC restated a “hold” rating and set a $180.00 price target on shares of Amgen in a report on Monday, May 22nd. Leerink Swann restated a “market perform” rating and set a $161.00 price target on shares of Amgen in a report on Thursday, June 22nd. Finally, Credit Suisse Group set a $177.00 price target on Amgen and gave the stock a “hold” rating in a report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $186.14.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.